drugset
Drugs / GcMAF
last change 13 days ago re-read 3 minutes ago

GcMAF

also known as Gc Macrophage Activating Factor · Gc protein macrophage-activating factor

Protein / enzyme biologic

Developed for
breast cancer
Investigated by
S.LAB (SOLOWAYS) · Center for New Medical Technologies, Novosibirsk, Russia · Center of New Medical Technologies

Trials 2

today NCT06877364 · Ph 1/2 NCT06434077 · Ph 3
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06877364 Sep 2025 — S.LAB (SOLOWAYS) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06434077 Aug 2025 → Sep 2026 overdue breast cancer S.LAB (SOLOWAYS) Not yet recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GcMAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT06877364 ↗
1

NCT06434077 ↗
Known as Gc Macrophage Activating Factor “This randomized, double-blind, placebo-controlled pilot study aims to evaluate the efficacy and safety of GcMAF (Gc Macrophage Activating Factor) in female patients with...” NCT06434077 ↗
Known as Gc protein macrophage-activating factor “The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.” NCT06434077 ↗
Action Inhibit “GcMAF in reducing nagalase levels” NCT06434077 ↗
Modality Protein / enzyme biologic “Gc protein macrophage-activating factor” NCT06434077 ↗
Route Subcutaneous “will be injected subcutaneously” NCT06434077 ↗